Although our results are limited by the fact that neither CDKN2A nor ANRIL expressions could be evaluated, they reveal that in humans, SNPs that affect CDKN2B expression are different from those that are known to affect CAD risk (Figure 4). The gene discussed is CDKN2B; the disease is coronary artery disorder.